Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II TAS-102 + bevacizumab + camrelizumab for third-line or later metastatic gastric cancer
ChiCTR2600129977Phase 2Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trifluridine + tipiracil, bevacizumab and camrelizumab in gastric adenocarcinoma and Esophago-Gastric Adenocarcinoma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-free survival (PFS). Started Aug 2026; status: recruiting.
02
Drugs
trifluridine + tipiracilbevacizumabcamrelizumab
03
Conditions
gastric adenocarcinomaEsophago-Gastric Adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2600129977.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600129977.